PATH SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter is Investigating the Acquisition of NuPathe, Inc. by Endo Health Solu...
17 Décembre 2013 - 6:31PM
Business Wire
The law firm of Wohl & Fruchter LLP is investigating the
acquisition of NuPathe, Inc. (NuPathe) (Nasdaq:PATH) by Endo Health
Solutions Inc. (Endo).
On December 16, 2013, NuPathe announced that Endo has agreed to
commence a tender offer to purchase all of the outstanding shares
of NuPathe common stock at a price of $2.85 per share, plus
contractual rights to receive up to an additional $3.15 per share
in contingent cash consideration payments, which will be payable
upon achieving certain net sales milestones of Zecuity®, NuPathe’s
FDA-approved migraine treatment. Zecuity® is the first and only
FDA-approved prescription migraine patch.
Wohl & Fruchter’s investigation concerns the adequacy of the
consideration being paid to PATH shareholders given the commercial
potential of Zecuity®, and whether the board of directors of
Nupathe breached their fiduciary duties to PATH shareholders by
failing to adequately shop the company.
Persons with relevant information, and PATH shareholders with
questions about this investigation, are invited to contact our Firm
by calling 866.833.6245, or contacting the attorney below.
Additional information is available
at http://www.wohlfruchter.com/cases/path.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation
arising from fraud and other fiduciary breaches by corporate
managers, as well as other complex litigation matters. Please visit
our website, www.wohlfruchter.com, to learn more about our Firm, or
contact one of our partners.
This release may be deemed to constitute attorney
advertising.
Wohl & Fruchter LLPJ. Elazar Fruchter,
845-425-4658jfruchter@wohlfruchter.comwww.wohlfruchter.com
Nupathe Inc. (MM) (NASDAQ:PATH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Nupathe Inc. (MM) (NASDAQ:PATH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Nupathe Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Nupathe Inc. (MM)